WO2021096186A1 - Cosmetic composition for skin improvement comprising taraxacum officinale leaf extract - Google Patents

Cosmetic composition for skin improvement comprising taraxacum officinale leaf extract Download PDF

Info

Publication number
WO2021096186A1
WO2021096186A1 PCT/KR2020/015654 KR2020015654W WO2021096186A1 WO 2021096186 A1 WO2021096186 A1 WO 2021096186A1 KR 2020015654 W KR2020015654 W KR 2020015654W WO 2021096186 A1 WO2021096186 A1 WO 2021096186A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
cosmetic composition
bacteria
present
improvement
Prior art date
Application number
PCT/KR2020/015654
Other languages
French (fr)
Korean (ko)
Inventor
김은지
김건휘
Original Assignee
주식회사 래디안
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 래디안 filed Critical 주식회사 래디안
Priority to CN202080079666.4A priority Critical patent/CN114728032A/en
Publication of WO2021096186A1 publication Critical patent/WO2021096186A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • Microbiome is a compound word of microbiota, which represents a microbial community, and genome, which represents a genome.
  • Microbiota is a term that focuses on the microbial strain itself compared to the microbiome. It refers to a microorganism that lives in the human body and has a symbiotic relationship. It refers to research and technology based on genomics of the interaction between the two. However, recently, microbiota, microflora, and microbiome, which mean microorganisms, are commonly used.
  • the term microbiome is better known as the intestinal microbiome, and inhibits harmful bacteria by ingesting lactic acid bacteria to expand the power of the intestinal lactic acid bacteria, and both lactic acid bacteria and harmful bacteria correspond to microbiome.
  • microbiome is receiving great attention in recent years. Since the association between the body's microbes and metabolic-related diseases such as obesity and diabetes has been revealed, the relationship between cancer, infection, immunity, and mental illness has been revealed, and microbiome-based therapeutics are emerging as one of the innovative treatment technologies. Maintaining the balance of the microbiome is well known to affect the functioning of the human body, and interest in microbiome research is increasing as research that the microbiome in the body is associated with obesity is revealed.
  • Patent Document 0001 Korean Patent Registration No. 10-1376202 (2014.03.13) discloses a pharmaceutical composition for preventing or treating skin diseases containing a mixture extract of dandelion and barley.
  • the present invention is to develop and provide a novel cosmetic composition having skin microbiome effect using a prebiotic material that increases the growth of lactic acid bacteria in the skin.
  • the present invention provides a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).
  • the cosmetic composition for improving skin of the present invention preferably promotes the growth of beneficial skin bacteria and inhibits the growth of harmful skin bacteria.
  • the beneficial bacteria are preferably Lactobacillus plantarum and Staphylococcus epidermidis.
  • the harmful bacteria are preferably Staphylococcus aureus and Propionibacterium acnes.
  • the cosmetic composition of the present invention promotes skin beneficial bacteria by activating the proliferation of lactic acid bacteria in the skin, does not kill and inhibits skin harmful bacteria, thereby exerting the effect of controlling the growth of beneficial skin bacteria and harmful bacteria.
  • FIG. 2 is a result of confirming changes in skin oil/moisture and pH of a subject during the treatment of Example 1.
  • Example 4 is a result of confirming the change in skin microbial distribution during treatment in Example 1 (Bad: Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium jeikeium, Corynebacterium diphtheriae, Streptococcus pyogenes, Streptococcus cristatus, Acinetobacter junii, Finephogoldia magna, Stenotrobacterium, Stenotrobacterium P.acne: Propionibacterium acnes, Normal: P.Koreensis, Propionibacterium qranulosum, Staphylococcus epidermidis, Streptococcus salivarius, Neisseria subflava, Staphylococcus warneri, Pseudomonas tolaaii, Acidovorax temperaceticans, Dietozia Lactobacillus, Bradyrhis , Lactobacillus rhamnosus HK
  • the present invention provides a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).
  • Probiotics control the composition of the microbiome, which also applies to the skin's microbiome.
  • a representative example of probiotics is lactic acid bacteria, and the lactic acid bacteria play a role of suppressing harmful bacteria by using a substance called bacteriocin.
  • bacteriocin a substance called bacteriocin.
  • probiotics live bacteria
  • a cosmetic material exceeds the microbial limit, so it is difficult to commercialize it. Therefore, it was attempted to develop a material having skin microbiome efficacy by using a prebiotic material that increases the growth of lactic acid bacteria in the skin.
  • the present invention provides a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).
  • the skin improvement is preferably an improvement in acne skin and an improvement in skin oil/moisture balance. It was confirmed through the following experiment that the extract of Western dandelion leaf of the present invention effectively improves the oil/moisture balance.
  • the cosmetic composition for improving skin of the present invention preferably promotes the growth of beneficial skin bacteria and inhibits the growth of harmful skin bacteria.
  • the beneficial bacteria are preferably Lactobacillus plantarum and Staphylococcus epidermidis
  • the harmful bacteria are preferably Staphylococcus aureus and Profi. It is better to be Propionibacterium acnes.
  • the extract of Western Dandelion leaves of the present invention increases the growth of Lactobacillus plantarum and Staphylococcus epidermidis, which are beneficial bacteria for skin, while increasing the growth of Staphylococcus epidermidis, Staphylococcus aureus, which is harmful to the skin ( Staphylococcus aureus) and Propionibacterium acnes.
  • Staphylococcus epidermidis which is a skin beneficial bacteria
  • the western dandelion leaf extract of the present invention treats the concentration of the preservative formulation applied to the finished product.
  • the extract is preferably contained in an amount of 0.00001 to 30.0% by weight based on the total weight of the cosmetic composition. More preferably, it is preferably contained in an amount of 0.01 to 10.0% by weight based on the total weight of the cosmetic composition.
  • the content of the mixed extract is less than 0.00001% by weight, skin improvement effects including improvement of acne skin and skin oil/moisture balance improvement do not appear, and when it exceeds 30.0% by weight, a distinct effect due to the increase in content does not increase.
  • ingredients included in the cosmetic composition of the present invention are active ingredients
  • components commonly used in cosmetic compositions may be included, and for example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers are included.
  • the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , Oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray may be formulated, but is not limited thereto.
  • it may be prepared in the form of a flexible lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.
  • a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene Glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethyleneglycol or fatty acid ester of sorbitan.
  • lactose When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • Propellants such as carbon, propane/butane or dimethyl ether.
  • the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing
  • carrier components aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters may be used.
  • the cosmetic composition of the present invention is a soap, a cleansing formulation containing a surfactant, or a cleansing formulation containing no surfactant
  • the soap is liquid soap, powder soap, solid soap and oil soap
  • the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel and cleansing pack
  • the cleansing formulation without surfactant is a cleansing cream , Cleansing lotion, cleansing water, and cleansing gel, but is not limited thereto.
  • the nucleotide sequence was analyzed using the 16S rRNA method, and it showed 99% homology with the standard strain, so it was deposited with the Biological Resource Center to receive the accession number SD1323.
  • the isolated lactic acid bacteria was named Lactobacillus plantarum RD-02, and was used in the following experiment to confirm the efficacy of the extract of the present invention on skin lactic acid bacteria.
  • Example 1 Preparation of the present invention Western dandelion leaf extract
  • the dried western dandelion leaves were pulverized finely using a grinder and then powdered. After mixing 50g of western dandelion leaf powder and 1L of purified water, an extract solution was prepared by stirring at 20 ⁇ 25°C for 1 hour using a stirrer. After the extraction solution was first filtered using a nonwoven filter paper, the first filtrate was changed to No. It was filtered under reduced pressure using 5C filter paper.
  • FIG. 2 is a result of confirming changes in skin oil/moisture and pH of a subject during the treatment of Example 1.
  • Bacterial porphyrin was reduced by about 25% when treated with Example 1. This value is a value derived from the bacterial porphyrin at the tip of the nose, and it was confirmed that the dot representing the bacterial porphyrin was decreased even at a region other than the tip of the nose (FIG. 3). 3 is a result of confirming changes in bacterial porphyrin during treatment in Example 1.
  • Example 4 is a result of confirming the change in skin microbial distribution during treatment in Example 1 (Bad: Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium jeikeium, Corynebacterium diphtheriae, Streptococcus pyogenes, Streptococcus cristatus, Acinetobacter junii, Finephogoldia magna, Stenotrobacterium, Stenotrobacterium P.acne: Propionibacterium acnes, Normal: P.Koreensis, Propionibacterium qranulosum, Staphylococcus epidermidis, Streptococcus salivarius, Neisseria subflava, Staphylococcus warneri, Pseudomonas tolaaii, Acidovorax temperaceticans, Dietzobium, Hs. , Lactobacillus rhamnosus HK-9, Bacill
  • the present invention relates to a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a cosmetic composition for skin improvement comprising a Taraxacum officinale leaf extract. The cosmetic composition of the present invention activates the proliferation of lactic acid bacteria in the skin to promote skin beneficial bacteria, and does not kill skin harmful bacteria but inhibits same, thereby exhibiting an effect of regulating the growth of skin beneficial bacteria and skin harmful bacteria.

Description

서양민들레잎 추출물을 포함하는 피부 개선용 화장료 조성물Cosmetic composition for skin improvement comprising extract of western dandelion leaf
본 발명은 서양민들레잎(Taraxacum officinale) 추출물을 포함하는 피부 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).
마이크로바이옴은 미생물군집을 나타내는 마이크로비오타와 유전체를 나타내는 게놈의 합성어이다. 마이크로비오타는 마이크로바이옴에 비해 미생물 균주 그 자체에 중점을 둔 용어로 인간의 몸에 서식하며 공생의 관계를 갖는 미생물을 뜻하고, 마이크로바이옴은 기존의 개별 미생물 분석 연구에서 벗어나 기주 생물과 미생물 간의 상호작용을 유전체학에 기반한 연구 및 기술을 뜻한다. 하지만, 최근에는 미생물을 뜻하는 마이크로비오타와 마이크로플로라, 마이크로바이옴을 통용하여 사용하고 있다. 마이크로바이옴이라는 용어는 장내 마이크로바이옴으로 더 잘 알려졌으며, 유산균을 섭취하여 장내 유산균의 세력을 확장시킴으로써 유해균을 억제하는 것으로, 유산균과 유해균 모두 마이크로바이옴에 해당한다.Microbiome is a compound word of microbiota, which represents a microbial community, and genome, which represents a genome. Microbiota is a term that focuses on the microbial strain itself compared to the microbiome. It refers to a microorganism that lives in the human body and has a symbiotic relationship. It refers to research and technology based on genomics of the interaction between the two. However, recently, microbiota, microflora, and microbiome, which mean microorganisms, are commonly used. The term microbiome is better known as the intestinal microbiome, and inhibits harmful bacteria by ingesting lactic acid bacteria to expand the power of the intestinal lactic acid bacteria, and both lactic acid bacteria and harmful bacteria correspond to microbiome.
최근 들어 마이크로바이옴이 크게 주목받는 이유 중 하나는 바로 인간의 건강과 질병 문제에 관한 적용 가능성이 크게 확대되면서부터이다. 체내 미생물과 비만, 당뇨 등 대사관련 질환의 연관성이 밝혀진 이후, 암, 감염, 면역, 정신질환 등과 관련성이 밝혀지며, 마이크로바이옴을 기반으로 한 치료제가 혁신적인 치료기술 중 하나로 부상하고 있다. 이처럼 마이크로바이옴의 균형을 유지하는 것은 인체의 기능에 영향을 미치는 것으로 잘 알려졌으며, 체내의 마이크로바이옴이 비만과 연관이 있다는 연구가 밝혀지면서 마이크로바이옴 연구에 대한 관심이 증가하고 있다.One of the reasons microbiome is receiving great attention in recent years is that its applicability to human health and disease issues has been greatly expanded. Since the association between the body's microbes and metabolic-related diseases such as obesity and diabetes has been revealed, the relationship between cancer, infection, immunity, and mental illness has been revealed, and microbiome-based therapeutics are emerging as one of the innovative treatment technologies. Maintaining the balance of the microbiome is well known to affect the functioning of the human body, and interest in microbiome research is increasing as research that the microbiome in the body is associated with obesity is revealed.
현재 형성되고 잇는 휴먼 마이크로바이옴 시장은 프로바이오틱(probiotics)과 프리바이오틱스(prebiotics)를 중심으로 한 기능성 식품 혹은 웬니스 제품 시장이 전체 시장의 83%를 차지한다. 건강기능성 프로바이오틱스 시장이 급속하게 커짐에 따라 식품뿐만 아니라 화장품, 의학, 제약 분야에서의 연구개발 수요가 급증하고 있다.In the currently forming human microbiome market, the functional food or Wennis product market, centered on probiotics and prebiotics, accounts for 83% of the total market. With the rapid growth of the health functional probiotics market, the demand for research and development in the fields of cosmetics, medicine, and pharmaceuticals as well as food is increasing rapidly.
최근에는 마이크로바이옴을 피부에 적용한 연구도 활발히 진행되고 있다. 피부에 유해한 미생물로 알려진 스타필로코커스 아우레우스(staphylococcus aureus)와 프로피오니박테리움 아크네(Propionibacterium acnes)가 증가하면서 피부에 유익한 미생물로 알려진 스타필로코커스 에피더미디스(Staphylococcus epidermidis)가 감소하면 피부의 여드름이 증가하는 것이 이미 연구로 알려진 바 있다. 이에 관한 예방 또는 회복을 위하여, 화장품 분야에서도 많은 연구가 진행되고 있지만, 대부분 유해균에 관한 방부 효과에 초점이 맞춰져 있을 뿐이다.Recently, research on applying microbiome to the skin is also actively being conducted. When Staphylococcus aureus and Propionibacterium acnes, known to be harmful to the skin, increase, and Staphylococcus epidermidis, known to be beneficial to the skin, decreases, The increase in acne has already been known by research. In order to prevent or recover from this, many studies are also being conducted in the cosmetic field, but most of them focus only on the antiseptic effect on harmful bacteria.
(특허문헌 0001) 대한민국등록특허 제10-1376202호(2014.03.13)에는, 민들레 및 보리 혼합 추출물을 함유하는 피부 질환의 예방, 또는 치료용 약학적 조성물에 관하여 개시되어 있다.(Patent Document 0001) Korean Patent Registration No. 10-1376202 (2014.03.13) discloses a pharmaceutical composition for preventing or treating skin diseases containing a mixture extract of dandelion and barley.
(특허문헌 0002) 대한민국등록특허 제10-1425757호(2014.07.25)에는, 여드름 개선용 피부 마사지 조성물 및 이를 포함하는 마스크팩에 관하여 개시되어 있다.(Patent Document 0002) Korean Patent Registration No. 10-1425757 (2014.07.25) discloses a skin massage composition for improving acne and a mask pack including the same.
본 발명은 피부 내 유산균의 생장을 증가시키는 프리바이오틱스 소재를 이용하여, 피부 마이크로바이옴 효능을 갖는 신규의 화장료 조성물을 개발하여 제공하고자 한다.The present invention is to develop and provide a novel cosmetic composition having skin microbiome effect using a prebiotic material that increases the growth of lactic acid bacteria in the skin.
본 발명은 서양민들레잎(Taraxacum officinale) 추출물을 포함하는 피부 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).
본 발명의 피부 개선용 화장료 조성물에 있어, 상기 피부 개선은, 바람직하게 여드름 피부의 개선, 피부 유/수분 밸런스 개선인 것이 좋다.In the cosmetic composition for improving skin of the present invention, the skin improvement is preferably an improvement in acne skin and an improvement in skin oil/moisture balance.
본 발명의 피부 개선용 화장료 조성물은 바람직하게 피부 유익균의 성장을 촉진하고, 피부 유해균의 생장을 억제하는 것이 좋다.The cosmetic composition for improving skin of the present invention preferably promotes the growth of beneficial skin bacteria and inhibits the growth of harmful skin bacteria.
본 발명의 피부 개선용 화장료 조성물에 있어, 상기 유익균은, 바람직하게 락토바실러스 플란타룸 (Lactobacillus plantarum) 및 스타필로코커스 에피더미디스(Staphylococcus epidermidis)인 것이 좋다.In the cosmetic composition for improving skin of the present invention, the beneficial bacteria are preferably Lactobacillus plantarum and Staphylococcus epidermidis.
본 발명의 피부 개선용 화장료 조성물에 있어, 상기 유해균은, 바람직하게 스타필로코커스 아우레우스 (Staphylococcus aureus) 및 프로피오니박테리움 아크네(Propionibacterium acnes)인 것이 좋다.In the cosmetic composition for improving skin of the present invention, the harmful bacteria are preferably Staphylococcus aureus and Propionibacterium acnes.
본 발명의 화장료 조성물은 피부에 있는 유산균의 증식을 활성화시켜 피부 유익균을 증진시키고, 피부 유해균을 사멸시키지 않고, 억제함으로써, 피부 유익균 및 유해균의 생장 조절 효과를 발휘한다.The cosmetic composition of the present invention promotes skin beneficial bacteria by activating the proliferation of lactic acid bacteria in the skin, does not kill and inhibits skin harmful bacteria, thereby exerting the effect of controlling the growth of beneficial skin bacteria and harmful bacteria.
도 1은 실시예 1의 피부 유산균(L.plantarum), 유익균(S.epidermidis)) 및 유해균(S. aureus 및 P.acne) 조절 효능을 평가한 결과이다.1 is a result of evaluating the efficacy of controlling skin lactic acid bacteria (L. plantarum), beneficial bacteria (S. epidermidis) and harmful bacteria (S. aureus and P. acne) of Example 1.
도 2는 실시예 1 처리 시, 피험자의 피부 유/수분, pH 변화를 확인한 결과이다.2 is a result of confirming changes in skin oil/moisture and pH of a subject during the treatment of Example 1. FIG.
도 3은 실시예 1 처리 시, 박테리아 포르피린 변화를 확인한 결과이다.3 is a result of confirming changes in bacterial porphyrin during treatment in Example 1.
도 4는 실시예 1 처리 시, 피부 미생물 분포 변화를 확인한 결과이다 (Bad: Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium jeikeium, Corynebacterium diphtheriae, Streptococcus pyogenes, Streptococcus cristatus, Acinetobacter junii, Finegoldia magna, Stenotrophomonas maltophilia, Corynebacterium pseudogenitalium, P.acne: Propionibacterium acnes, Normal: P.Koreensis, Propionibacterium qranulosum, Staphylococcus epidermidis, Streptococcus salivarius, Neisseria subflava, Staphylococcus warneri, Pseudomonas tolaaii, Acidovorax temperans, Dietzia maris, Bradyrhizobium japonicum, Acinetobater calcoaceticus , Good: Lactobacillus paracasei HS-05, Lactobacillus rhamnosus HK-9, Bacillus licheniformis, Bacillus subtilis).4 is a result of confirming the change in skin microbial distribution during treatment in Example 1 (Bad: Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium jeikeium, Corynebacterium diphtheriae, Streptococcus pyogenes, Streptococcus cristatus, Acinetobacter junii, Finephogoldia magna, Stenotrobacterium, Stenotrobacterium P.acne: Propionibacterium acnes, Normal: P.Koreensis, Propionibacterium qranulosum, Staphylococcus epidermidis, Streptococcus salivarius, Neisseria subflava, Staphylococcus warneri, Pseudomonas tolaaii, Acidovorax temperaceticans, Dietozia Lactobacillus, Bradyrhis , Lactobacillus rhamnosus HK-9, Bacillus licheniformis, Bacillus subtilis).
본 발명은 서양민들레잎(Taraxacum officinale) 추출물을 포함하는 피부 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).
프로바이오틱스는 마이크로바이옴의 구성을 조절하는 기능을 하며, 이는 피부의 마이크로바이옴에도 적용된다. 프로바이오틱스의 대표적인 예로 유산균을 들 수 있으며, 유산균은 박테리오신(bacteriocin)이라는 물질을 이용하여 유해균을 억제하는 역할을 한다. 기존 연구를 통해 특정 유산균과 대사산물이 아토피 등 피부질환에 효능이 있는 것을 확인할 수 있었다.Probiotics control the composition of the microbiome, which also applies to the skin's microbiome. A representative example of probiotics is lactic acid bacteria, and the lactic acid bacteria play a role of suppressing harmful bacteria by using a substance called bacteriocin. Existing studies have confirmed that certain lactic acid bacteria and metabolites are effective against skin diseases such as atopy.
그러나 프로바이오틱스(생균)를 화장품 소재로 사용하기엔 미생물 한도를 초과하기 때문에 실제 제품화에 어려움이 있다. 따라서, 피부 내 유산균의 생장을 증가시키는 프리바이오틱스 소재를 이용해 피부 마이크로바이옴 효능을 갖는 소재를 개발하고자 하였다.However, the use of probiotics (live bacteria) as a cosmetic material exceeds the microbial limit, so it is difficult to commercialize it. Therefore, it was attempted to develop a material having skin microbiome efficacy by using a prebiotic material that increases the growth of lactic acid bacteria in the skin.
이에, 본 발명은 서양민들레잎(Taraxacum officinale) 추출물을 포함하는 피부 개선용 화장료 조성물을 제공한다.Accordingly, the present invention provides a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).
프로바이오틱스의 영양원으로 잘 알려진 당류를 함유한 소재의 경우, 추후 화장품에 적용 시, 제형 불안정의 우려가 있다. 이에, 본 출원인은 서양민들레잎(Taraxacum officinale)의 프로바이오틱스 효능이 매우 뛰어남을 확인하고, 본 발명의 재료로 선택하였다.In the case of a material containing sugars, which is well known as a nutrient source of probiotics, there is a concern of formulation instability when applied to cosmetics in the future. Accordingly, the applicant of the present invention confirmed that the probiotic efficacy of Western dandelion leaves (Taraxacum officinale) was very excellent, and was selected as the material of the present invention.
본 발명의 피부 개선용 화장료 조성물에 있어, 상기 피부 개선은, 바람직하게 여드름 피부의 개선, 피부 유/수분 밸런스 개선인 것이 좋다. 본 발명의 서양민들레잎 추출물이 유/수분 밸런스를 효과적으로 개선시킴을 하기 실험을 통해 확인할 수 있었다.In the cosmetic composition for improving skin of the present invention, the skin improvement is preferably an improvement in acne skin and an improvement in skin oil/moisture balance. It was confirmed through the following experiment that the extract of Western dandelion leaf of the present invention effectively improves the oil/moisture balance.
본 발명의 피부 개선용 화장료 조성물은 바람직하게 피부 유익균의 성장을 촉진하고, 피부 유해균의 생장을 억제하는 것이 좋다. 이때, 상기 유익균은, 바람직하게 락토바실러스 플란타룸 (Lactobacillus plantarum) 및 스타필로코커스 에피더미디스(Staphylococcus epidermidis)인 것이 좋고, 상기 유해균은, 바람직하게 스타필로코커스 아우레우스 (Staphylococcus aureus) 및 프로피오니박테리움 아크네(Propionibacterium acnes)인 것이 좋다.The cosmetic composition for improving skin of the present invention preferably promotes the growth of beneficial skin bacteria and inhibits the growth of harmful skin bacteria. At this time, the beneficial bacteria are preferably Lactobacillus plantarum and Staphylococcus epidermidis, and the harmful bacteria are preferably Staphylococcus aureus and Profi. It is better to be Propionibacterium acnes.
하기 실험에서 본 발명의 서양민들레잎 추출물은 피부 유익균인 락토바실러스 플란타룸 (Lactobacillus plantarum) 및 스타필로코커스 에피더미디스 (Staphylococcus epidermidis)의 생장을 증가시키면서, 피부 유해균인 스타필로코커스 아우레우스 (Staphylococcus aureus) 및 프로피오니박테리움 아크네 (Propionibacterium acnes)의 생장을 효과적으로 감소시킴을 확인할 수 있었다. 특히, 화장품 방부제에 의해 피부 유익균인 스타필로코커스 에피더미디스 (Staphylococcus epidermidis)가 사멸되면서 마이크로바이옴 밸런스가 무너지게 되는데, 본 발명의 서양민들레잎 추출물은 방부 제형이 완제품에 적용되는 농도를 처리하여 실험을 수행한 결과, 스타필로코커스 에피더미디스 (Staphylococcus epidermidis)의 생장을 증가시킴이 확인된바 (미도시), 상기한 문제를 해소할 수 있다.In the following experiment, the extract of Western Dandelion leaves of the present invention increases the growth of Lactobacillus plantarum and Staphylococcus epidermidis, which are beneficial bacteria for skin, while increasing the growth of Staphylococcus epidermidis, Staphylococcus aureus, which is harmful to the skin ( Staphylococcus aureus) and Propionibacterium acnes. In particular, as Staphylococcus epidermidis, which is a skin beneficial bacteria, is killed by cosmetic preservatives, the microbiome balance is destroyed.The western dandelion leaf extract of the present invention treats the concentration of the preservative formulation applied to the finished product. As a result of performing the experiment, it was confirmed that the growth of Staphylococcus epidermidis is increased (not shown), and the above problem can be solved.
한편, 본 발명에 있어, 상기 추출물은, 바람직하게 화장료 조성물 전체 중량에 대하여 0.00001~30.0중량%가 함유되는 것이 좋다. 더욱 바람직하게는 화장료 조성물 전체 중량에 대해서 0.01~10.0중량% 함유되는 것이 좋다. 혼합 추출물의 함량이 0.00001중량% 미만인 경우에는 여드름 피부의 개선, 피부 유/수분 밸런스 개선을 포함하는 피부 개선 효과가 나타나지 않고, 30.0중량% 초과할 경우 함유량 증가에 따른 뚜렷한 효과가 증가하지 않는다.Meanwhile, in the present invention, the extract is preferably contained in an amount of 0.00001 to 30.0% by weight based on the total weight of the cosmetic composition. More preferably, it is preferably contained in an amount of 0.01 to 10.0% by weight based on the total weight of the cosmetic composition. When the content of the mixed extract is less than 0.00001% by weight, skin improvement effects including improvement of acne skin and skin oil/moisture balance improvement do not appear, and when it exceeds 30.0% by weight, a distinct effect due to the increase in content does not increase.
한편, 본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서On the other hand, the ingredients included in the cosmetic composition of the present invention are active ingredients
본 발명의 혼합 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.In addition to the mixed extract of the present invention, components commonly used in cosmetic compositions may be included, and for example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers are included.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 팩, 마사지크림 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , Oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray may be formulated, but is not limited thereto. In more detail, it may be prepared in the form of a flexible lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream, or gel, as a carrier component, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. Can be used.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene Glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethyleneglycol or fatty acid ester of sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Propellants such as carbon, propane/butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters may be used.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 제형 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클렌징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비 함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, a cleansing formulation containing a surfactant, or a cleansing formulation containing no surfactant, it may be applied to the skin and then wiped off, removed, or washed off with water. As a specific example, the soap is liquid soap, powder soap, solid soap and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel and cleansing pack, and the cleansing formulation without surfactant is a cleansing cream , Cleansing lotion, cleansing water, and cleansing gel, but is not limited thereto.
이하, 본 발명의 구성을 하기 실시예 및 실험예를 통해 구체적으로 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예 및 실험예에만 한정되는 것은 아니고, 그와 등가의 기술적 사상의 변형까지를 포함한다.Hereinafter, the configuration of the present invention will be described in detail through the following examples and experimental examples. However, the scope of the present invention is not limited to the following examples and experimental examples, and includes modifications of equivalent technical ideas.
(실험예 1: 피부 유산균 분리 동정)(Experimental Example 1: Isolation and Identification of Lactobacillus Skin)
44명의 남녀 피험자를 대상으로 안면, 볼 및 손바닥의 피부 표면 미생물을 스왑하였다. 스왑 면봉을 튜브에 넣고 농화배양을 진행한 뒤, 배양액을 BHI 아가배지에 배양하여 콜로니를 획득하였다. 다수의 단일 콜로니를 각각의 BHI 배지에 배양한 뒤, 배양 균주에 대한 유산균 판별을 위해 주식회사 마크로젠에 시퀀싱 분석을 의뢰하였다.In 44 male and female subjects, microbes on the skin surface of the face, cheeks, and palms were swapped. After the swab was put into the tube and concentrated culture was performed, the culture solution was cultured on BHI agar medium to obtain colonies. After culturing a plurality of single colonies in each BHI medium, a sequencing analysis was requested to Macrogen Co., Ltd. to determine the lactic acid bacteria for the cultured strain.
분리한 균주의 동정은 16S rRNA 방법을 사용하여 염기서열을 분석하였으며, 표준균주와 99%의 상동성을 나타내어 생물자원센터에 기탁하여 기탁번호 SD1323을 부여받았다. 분리한 유산균은 락토바실러스 플란타룸(Lactobacillus plantarum) RD-02로 명명하였고, 본 발명의 추출물의 피부 유산균에 관한 효능을 확인하기 위하여 하기 실험에서 사용하였다.For the identification of the isolated strain, the nucleotide sequence was analyzed using the 16S rRNA method, and it showed 99% homology with the standard strain, so it was deposited with the Biological Resource Center to receive the accession number SD1323. The isolated lactic acid bacteria was named Lactobacillus plantarum RD-02, and was used in the following experiment to confirm the efficacy of the extract of the present invention on skin lactic acid bacteria.
(실시예 1: 본 발명 서양민들레잎 추출물의 제조)(Example 1: Preparation of the present invention Western dandelion leaf extract)
건조된 서양민들레잎을 분쇄기를 이용하여 잘게 분쇄하여 분말화하였다. 서양민들레잎 분말 50g과 정제수 1L를 혼합한 후, 교반기를 이용하여 20~25℃에서 1시간 동안 교반하여 추출용액을 제조하였다. 추출용액을 부직포 여과지를 이용하여 추출용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과하였다.The dried western dandelion leaves were pulverized finely using a grinder and then powdered. After mixing 50g of western dandelion leaf powder and 1L of purified water, an extract solution was prepared by stirring at 20~25℃ for 1 hour using a stirrer. After the extraction solution was first filtered using a nonwoven filter paper, the first filtrate was changed to No. It was filtered under reduced pressure using 5C filter paper.
(실험예 2: 피부 미생물 조절 효능 평가)(Experimental Example 2: Evaluation of skin microbial control efficacy)
피부 미생물 조절 효능을 평가하기 위하여, 피부 유산균인 '락토바실러스 플란타룸 RD-02 (Lactobacillus plantarum RD-02)와 스타필로코커스 에피더미디스 (Staphylococcus epidermidis)', '락토바실러스 플란타룸 RD02 (Lactobacillus plantarum RD-02)와 스타필로코커스 아우레우스 (Staphylococcus aureus)', '락토바실러스 플란타룸 RD-02 (Lactobacillus plantarum RD-02)와 프로피오니박테리움 아크네 (Propionibacterium acnes)'를 동일 농도로 혼합하여 각각 공생배양하였으며, 서양민들레잎 추출물을 처리하여 함께 배양하였다. 이후 배양액을 희석하여 아가배지에 스프레딩한 뒤 배양된 각 미생물들의 콜로니를 카운팅하여 미생물 수의 변화를 확인하였다.In order to evaluate the skin microbial control efficacy, the skin lactic acid bacteria'Lactobacillus plantarum RD-02 (Lactobacillus plantarum RD-02) and Staphylococcus epidermidis','Lactobacillus plantarum RD02 (Lactobacillus) plantarum RD-02) and Staphylococcus aureus', Lactobacillus plantarum RD-02 (Lactobacillus plantarum RD-02) and Propionibacterium acnes' at the same concentration. Then, they were cultured together with each other, and treated with the extract of Western dandelion leaves and cultured together. Thereafter, the culture solution was diluted and spread on an agar medium, and then the colonies of each cultured microorganism were counted to confirm the change in the number of microorganisms.
실험 결과, 서양민들레잎 추출물이 피부 유산균인 락토바실러스 플란타룸 RD-02 (기탁번호 SD1323)의 증식을 활성화시킴으로써, 피부의 유익균인 스타필로코커스 에피더미디스의 생장을 유의하게 증가시켰고, 피부 유해균인 스타필로코커스 아우레우스 (Staphylococcus aureus) 및 프로피오니박테리움 아크네 (Propionibacterium acnes)의 생장을 유의하게 감소시킴을 확인할 수 있었다 (도 1). 도 1은 실시예 1의 피부 유산균(L.plantarum), 유익균(S. epidermidis)) 및 유해균(S. aureus 및 P.acne) 조절 효능을 평가한 결과이다.As a result of the experiment, by activating the proliferation of Lactobacillus plantarum RD-02 (accession number SD1323), a skin lactic acid bacteria, the extract of Western Dandelion leaves significantly increased the growth of Staphylococcus epidermidis, a beneficial bacteria of the skin, and harmful bacteria for the skin. In Staphylococcus aureus (Staphylococcus aureus) and Propionibacterium acne (Propionibacterium acnes) was confirmed to significantly reduce the growth (Fig. 1). 1 is a result of evaluating the efficacy of controlling skin lactic acid bacteria (L. plantarum), beneficial bacteria (S. epidermidis) and harmful bacteria (S. aureus and P. acne) of Example 1.
(실험예 3: 피부 안전성 평가)(Experimental Example 3: Skin safety evaluation)
피부 안전성을 확인하기 위하여 인체 첩포 실험을 수행하였다. 건강한 성인 여자 20명의 팔 안쪽 부위에 Finn chamber 키트를 이용하여 희석된 시료를 처리하여 피부에 고정하였다. 판정기준은 국제 접촉피부염 연구위원회 (International contact dermatitis research group)의 기준에 따랐다. 실험 결과, 본 발명의 서양민들레 추출물은 자극이 없는 것으로 확인되었다 (표 1).In order to confirm the safety of the skin, a human patch experiment was performed. The diluted sample was treated on the inner part of the arm of 20 healthy adult women using the Finn chamber kit and fixed to the skin. The criteria for the judgment were based on the standards of the International Contact Dermatitis Research Group. As a result of the experiment, it was confirmed that the extract of Western dandelion of the present invention was not irritated (Table 1).
시료sample 피시험지수Index under test 판정결과Judgment result 자극도Irritation
++++ ++ ±± --
실시예 1Example 1 2020 00 00 00 2020 00
대조군 Control 2020 00 00 00 2020 00
(판정기준)
- : 홍반이나 특이한 현상 없음
± : 주위보다 약간 붉어짐
+ : 주위보다 현저히 붉어짐
++ : 주위보다 심하게 붉어지고 부풀어 오름
(자극도 계산식)
자극도 = [{(±)수×1}+{(+)수×2}+{(++)수×3}/피시험자수
(Criteria)
-: No erythema or unusual phenomena
±: slightly redder than the surrounding area
+: Remarkably redder than surroundings
++: Reddens and swells more severely than the surroundings
(Irritation degree calculation formula)
Stimulus = [{(±) number×1}+{(+) number×2}+{(++) number×3}/number of subjects
(실험예 4: 피부 개선 효능 평가)(Experimental Example 4: Evaluation of skin improvement efficacy)
실제 피부에 적용하였을 시, 개선효과를 확인하기 위하여, 희석된 실시예 1의 시료(건조중량 0.05% 농도)를 피부에 도포한 뒤, 피부의 유/수분, pH, 박테리아 포르피린 및 미생물의 분포 변화를 확인하였다.When applied to the actual skin, after applying the diluted sample of Example 1 (0.05% dry weight concentration) to the skin in order to confirm the improvement effect, changes in the oil/moisture, pH, distribution of bacterial porphyrin and microorganisms of the skin Was confirmed.
유/수분 및 pH 측정은 Callegari s.r.l사의 Soft Plus 기기를 사용하였고, 박테리아 포르피린 측정은 Sylton diagnostic system 사의 OBSERV 기기를 사용하였다. 피부 미생물의 변화는 세바바이오텍에 분석을 의뢰하였다.The oil/moisture and pH measurements were performed using a Soft Plus instrument manufactured by Callegari s.r.l, and the OBSERV instrument manufactured by Sylton Diagnostic System was used to measure bacterial porphyrin. Changes in skin microbes were analyzed by Seva Biotech.
실험 결과, 실시예 1의 처리에 따라 피부의 유/수분 수치가 정상 피부의 수준으로 개선되었다. 모든 피험자에 대한 평균으로 보았을 때, 수분은 10% 개선되었으며, 유분은 20% 개선되었다 (도 2). 도 2는 실시예 1 처리 시, 피험자의 피부 유/수분, pH 변화를 확인한 결과이다.As a result of the experiment, according to the treatment of Example 1, the oil/moisture level of the skin was improved to the level of normal skin. When viewed as an average for all subjects, moisture was improved by 10% and oil content was improved by 20% (FIG. 2). 2 is a result of confirming changes in skin oil/moisture and pH of a subject during the treatment of Example 1. FIG.
박테리아 포르피린은 실시예 1 처리 시, 약 25%가 감소되었다. 이 수치는 코 끝 부분의 박테리아 포르피린을 대상으로 도출한 수치이며, 코 끝 이외의 부위에서도 박테리아 포르피린을 나타내는 Dot이 감소됨을 확인할 수 있었다 (도 3). 도 3은 실시예 1 처리 시, 박테리아 포르피린 변화를 확인한 결과이다.Bacterial porphyrin was reduced by about 25% when treated with Example 1. This value is a value derived from the bacterial porphyrin at the tip of the nose, and it was confirmed that the dot representing the bacterial porphyrin was decreased even at a region other than the tip of the nose (FIG. 3). 3 is a result of confirming changes in bacterial porphyrin during treatment in Example 1.
한편, 미생물 분포 변화를 확인한 결과, 실시예 1 처리 시, bad type의 미생물 군집과 P.acne 군집의 분포가 감소하였으며, normal type과 good type의 미생물 군집 분포가 증가하였다 (도 4). 도 4는 실시예 1 처리 시, 피부 미생물 분포 변화를 확인한 결과이다 (Bad: Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium jeikeium, Corynebacterium diphtheriae, Streptococcus pyogenes, Streptococcus cristatus, Acinetobacter junii, Finegoldia magna, Stenotrophomonas maltophilia, Corynebacterium pseudogenitalium, P.acne: Propionibacterium acnes, Normal: P.Koreensis, Propionibacterium qranulosum, Staphylococcus epidermidis, Streptococcus salivarius, Neisseria subflava, Staphylococcus warneri, Pseudomonas tolaaii, Acidovorax temperans, Dietzia maris, Bradyrhizobium japonicum, Acinetobater calcoaceticus, Good: Lactobacillus paracasei HS-05, Lactobacillus rhamnosus HK-9, Bacillus licheniformis, Bacillus subtilis).On the other hand, as a result of confirming the change in the distribution of microorganisms, when treated in Example 1, the distribution of the bad type microbial community and the P.acne community decreased, and the normal type and good type microbial community distribution increased (Fig. 4). 4 is a result of confirming the change in skin microbial distribution during treatment in Example 1 (Bad: Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium jeikeium, Corynebacterium diphtheriae, Streptococcus pyogenes, Streptococcus cristatus, Acinetobacter junii, Finephogoldia magna, Stenotrobacterium, Stenotrobacterium P.acne: Propionibacterium acnes, Normal: P.Koreensis, Propionibacterium qranulosum, Staphylococcus epidermidis, Streptococcus salivarius, Neisseria subflava, Staphylococcus warneri, Pseudomonas tolaaii, Acidovorax temperaceticans, Dietzobium, Hs. , Lactobacillus rhamnosus HK-9, Bacillus licheniformis, Bacillus subtilis).
본 발명은 서양민들레잎(Taraxacum officinale) 추출물을 포함하는 피부 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin comprising an extract of Western dandelion leaves (Taraxacum officinale).

Claims (5)

  1. 서양민들레잎(Taraxacum officinale) 추출물을 포함하는 피부 개선용 화장료 조성물.Western dandelion leaf (Taraxacum officinale) cosmetic composition for skin improvement comprising an extract.
  2. 제1항에 있어서,The method of claim 1,
    상기 피부 개선은,The skin improvement,
    여드름 피부의 개선, 피부 유/수분 밸런스 개선인 것을 특징으로 하는 피부 개선용 화장료 조성물.A cosmetic composition for improving skin, characterized in that it improves acne skin and improves skin oil/moisture balance.
  3. 제1항에 있어서,The method of claim 1,
    상기 화장료 조성물은,The cosmetic composition,
    피부 유익균의 성장을 촉진하고, 피부 유해균의 생장을 억제하는 것을 특징으로 하는 피부 개선용 화장료 조성물.A cosmetic composition for improving skin, characterized in that it promotes the growth of beneficial skin bacteria and inhibits the growth of harmful skin bacteria.
  4. 제3항에 있어서,The method of claim 3,
    상기 유익균은,The beneficial bacteria are,
    락토바실러스 플란타룸 (Lactobacillus plantarum) 및 스타필로코커스 에피더미디스 (Staphylococcus epidermidis)인 것을 특징으로 하는 피부 개선용 화장료 조성물.Cosmetic composition for skin improvement, characterized in that Lactobacillus plantarum (Lactobacillus plantarum) and Staphylococcus epidermidis (Staphylococcus epidermidis).
  5. 제3항에 있어서,The method of claim 3,
    상기 유해균은,The harmful bacteria,
    스타필로코커스 아우레우스 (Staphylococcus aureus) 및 프로피오니박테리움 아크네 (Propionibacterium acnes)인 것을 특징으로 하는 피부 개선용 화장료 조성물.Staphylococcus aureus (Staphylococcus aureus) and Propionibacterium acne (Propionibacterium acnes), characterized in that the cosmetic composition for skin improvement.
PCT/KR2020/015654 2019-11-11 2020-11-09 Cosmetic composition for skin improvement comprising taraxacum officinale leaf extract WO2021096186A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080079666.4A CN114728032A (en) 2019-11-11 2020-11-09 A cosmetic composition containing Taraxacum officinale extract for improving skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190143775A KR102121006B1 (en) 2019-11-11 2019-11-11 Cosmetic composition for improvement of skin with Taraxacum officinale
KR10-2019-0143775 2019-11-11

Publications (1)

Publication Number Publication Date
WO2021096186A1 true WO2021096186A1 (en) 2021-05-20

Family

ID=71082525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/015654 WO2021096186A1 (en) 2019-11-11 2020-11-09 Cosmetic composition for skin improvement comprising taraxacum officinale leaf extract

Country Status (3)

Country Link
KR (1) KR102121006B1 (en)
CN (1) CN114728032A (en)
WO (1) WO2021096186A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102121006B1 (en) * 2019-11-11 2020-06-09 주식회사 래디안 Cosmetic composition for improvement of skin with Taraxacum officinale
KR102270709B1 (en) 2021-04-15 2021-06-28 경호빈 Cosmetic composition for skin improvement containing complex ceramide and natural extracts
KR102663083B1 (en) 2021-04-29 2024-05-03 국민대학교산학협력단 Composition for Improving Skin Microbiome Comprising Rhapontici Radix Extract
KR102386262B1 (en) 2022-01-17 2022-04-14 주식회사 지웨이코스메틱 Cosmetics composition with Extract of Sparassis crispa Wulf. ex Fr. and extract of Taraxacum officinale leaf and fermentation lysate of Lactobacillus and palm oil fraction
KR102565684B1 (en) * 2023-04-13 2023-08-10 주식회사 에스지엔바이오 Cosmetic composition for improving acne containing Taraxacum platycarpum extract, vitamins and peptides as active ingredients
KR102604529B1 (en) * 2023-06-30 2023-11-23 박준한 Cosmetic composition for skin improvement containing stem cell culture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1036279A (en) * 1996-07-18 1998-02-10 Ichimaru Pharcos Co Ltd Fibroblast proliferation promoting agent containing vegetable extract
KR100771397B1 (en) * 2006-06-08 2007-10-30 인제대학교 산학협력단 Cosmetic composition comprising an extract of dandelion or luteolin isolated therefrom having anti-oxidant activity and anti-inflammatory activity
KR20100067773A (en) * 2008-12-12 2010-06-22 보령메디앙스 주식회사 Cosmetic composition comprising mixture extract and preparation thereof
KR101901451B1 (en) * 2018-01-23 2018-09-27 (주)해피엘앤비 Cosmetic composition containing flower extracts prepared by a method based on natural deep eutectic Solvents
KR102121006B1 (en) * 2019-11-11 2020-06-09 주식회사 래디안 Cosmetic composition for improvement of skin with Taraxacum officinale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101376202B1 (en) 2012-05-15 2014-03-26 한국원자력연구원 Pharmaceutical composition containing extract of mongolian dandelion and barley for the provention or treatment of skin disease
KR101425757B1 (en) 2013-09-12 2014-08-05 김태홍 Herbal skin massage composition and the mask pack comprising the same
KR101753306B1 (en) * 2014-08-11 2017-07-04 경희대학교 산학협력단 A cosmetic composition for improving skin winkle
KR20160054668A (en) * 2014-11-06 2016-05-17 주식회사 엘지생활건강 Composition for promoting synthesis of hyaluronic acid comprising Taraxacum herbs extracts and the use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1036279A (en) * 1996-07-18 1998-02-10 Ichimaru Pharcos Co Ltd Fibroblast proliferation promoting agent containing vegetable extract
KR100771397B1 (en) * 2006-06-08 2007-10-30 인제대학교 산학협력단 Cosmetic composition comprising an extract of dandelion or luteolin isolated therefrom having anti-oxidant activity and anti-inflammatory activity
KR20100067773A (en) * 2008-12-12 2010-06-22 보령메디앙스 주식회사 Cosmetic composition comprising mixture extract and preparation thereof
KR101901451B1 (en) * 2018-01-23 2018-09-27 (주)해피엘앤비 Cosmetic composition containing flower extracts prepared by a method based on natural deep eutectic Solvents
KR102121006B1 (en) * 2019-11-11 2020-06-09 주식회사 래디안 Cosmetic composition for improvement of skin with Taraxacum officinale

Also Published As

Publication number Publication date
KR102121006B1 (en) 2020-06-09
CN114728032A (en) 2022-07-08

Similar Documents

Publication Publication Date Title
WO2021096186A1 (en) Cosmetic composition for skin improvement comprising taraxacum officinale leaf extract
RU2683225C2 (en) Novel lactic acid bacteria and compositions containing same
WO2022158656A1 (en) Composition for controlling dermatological microorganisms
KR102587334B1 (en) Strains for improving skin, and kit for improving skin using the same
CN111826300B (en) Bifidobacterium animalis subspecies lactis GFC-B09 strain and cosmetic composition containing same
WO2019004684A2 (en) Cosmetic composition for reducing skin wrinkle or moisturizing skin, comprising nano-sized kimchi lactic acid bacteria
CA2886575C (en) Composition for removing keratinous skin material comprising green tea lactobacillus
KR102293593B1 (en) Skin external composition comprising Asparagopsis taxiformis extract and functional food comprising extract of Asparagopsis taxiformis extract
KR101770140B1 (en) Lactobacillus fermentum HK and Phormium tenax Fermented extract Manufactured Using Thereof
KR102270709B1 (en) Cosmetic composition for skin improvement containing complex ceramide and natural extracts
KR102226187B1 (en) Lactobacillus iners AHC2030 and Fermented Product Manufactured Using Thereof
CN115038425B (en) Cosmetic composition for improving skin comprising polysaccharide, yeast extract and strain fermentation product with probiotic properties as effective components
KR20220004328A (en) Composition for maintaining the balance of microbiome in the skin comprising hampseed oil
CN110613648A (en) Skin care composition capable of improving skin barrier and application thereof
CN114938629A (en) Novel skin care compositions
KR102293592B1 (en) Skin external composition comprising extract of Martensia jejuensis and functional food comprising extract of Martensia jejuensis
KR102280751B1 (en) Lactobacillus plantarum YoungBiome2 and Titrated Extract of Fermented Centella Asiatica Manufactured Using Thereof
KR102441226B1 (en) A composition for skin microbiome comprising mixed probiotics fermentation product and cosmetic composition comprising the same
JP2019119689A (en) Skin condition improving agent
CN114711429A (en) Lactobacillus reuteri with bone health enhancing effect and application thereof
CN111447919B (en) Composition for skin whitening comprising culture of bacillus caldus or extract thereof
JP2022055482A (en) Skin flora improver and topical skin preparation for improved skin flora
KR102653020B1 (en) A cosmetic composition containing fermented extract of Lactiplantibacillus plantarum OPT-antiUV strain
KR102194314B1 (en) Antioxidant or skin microbiome balance cosmetic composition comprising green tea fermented extract fermented by inoculating lactobacillus rhamnosus strain
WO2022039379A1 (en) Composition for preventing or ameliorating bromhidrosis comprising seed fermentation product of lotus corniculatus genus plant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20887266

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20887266

Country of ref document: EP

Kind code of ref document: A1